Search results for "Azepine"

showing 10 items of 266 documents

Altered receptor subtypes in the forebrain of GABAA receptor δ subunit-deficient mice: recruitment of γ2 subunits

2002

A GABA(A) receptor delta subunit-deficient mouse line was created by homologous recombination in embryonic stem cells to investigate the role of the subunit in the brain GABA(A) receptors. High-affinity [(3)H]muscimol binding to GABA sites as studied by ligand autoradiography was reduced in various brain regions of delta(-/-) animals. [(3)H]Ro 15-4513 binding to benzodiazepine sites was increased in delta(-/-) animals, partly due to an increment of diazepam-insensitive receptors, indicating an augmented forebrain assembly of gamma 2 subunits with alpha 4 subunits. In the western blots of forebrain membranes of delta(-/-) animals, the level of gamma 2 subunit was increased and that of alpha …

MaleAzidesProtein subunitBiologyTritiumSynaptic TransmissionIon ChannelsGABAA-rho receptorInterleukin 10 receptor alpha subunitBenzodiazepinesMiceRadioligand Assaychemistry.chemical_compoundAnimalsReceptorGABA Agonistsgamma-Aminobutyric AcidMice KnockoutNeuronsBinding SitesMuscimolGABAA receptorGeneral NeuroscienceBrainAffinity LabelsNeural InhibitionReceptors GABA-AMolecular biologynervous systemMuscimolchemistryMutationForebrainFemaleCys-loop receptorsNeuroscience
researchProduct

Fasted-state simulated intestinal fluid "FaSSIF-C", a cholesterol containing intestinal model medium for in vitro drug delivery development.

2015

A set of biorelevant media "fasted-state simulated intestinal fluid with cholesterol (FaSSIF-C)" for the in vitro study of intestinal drug dissolution in the duodenum was developed. These contain cholesterol at the same levels as in human bile: the cholesterol content of FaSSIF-7C is equivalent to healthy female, FaSSIF-10C to healthy male persons, and FaSSIF-13C to several disease cases that lead to gallstones. The fluids were studied in three aspects: biocompatibility, intestinal nanostructure, and solubilizing power of hydrophobic drugs of the BCS class II. The biocompatibility study showed no toxic effects in a Caco-2 cell system. The drug-solubilizing capacity toward Fenofibrate, Danaz…

MaleBiocompatibilityPharmaceutical ScienceMicelleHigh cholesterolGriseofulvinchemistry.chemical_compoundDrug Delivery SystemsFenofibratemedicineHumansDissolution testingIntestinal MucosaParticle SizeFenofibrateChromatographyCholesterolDanazolFastingModels TheoreticalGriseofulvinmedicine.diseaseBody FluidsCarbamazepineCholesterolchemistryIntestinal AbsorptionSolubilityDrug deliveryFemaleCaco-2 Cellsmedicine.drugJournal of pharmaceutical sciences
researchProduct

Oral lichenoid drug reaction by lithium in a patient with bipolar disorder

2005

Bipolar disorder (BD) is a psychiatric disease characterized by recurrent and alternated episodes of depression and mania. For the treatment of BD, anticonvulsants drugs as lithium, carbamazepine and oxcarbazepine can be used. These drugs can be associated with potential adverse effects: weight gain, tremors, thyroid abnormalities, and cognitive, gastrointestinal, cardiac or dermatological problems. We describe a case of BD with oral lichenoid drug reaction probably because of the mood stabilizers.

MaleCancer Researchmedicine.medical_specialtyBipolar DisorderLichenoid EruptionsLithium (medication)antipsychotics bipolar disorders drug reaction lichenoid lesions lithium therapyPathology and Forensic Medicinechemistry.chemical_compoundLithium CarbonateAntimanic Agentsmental disordersmedicineHumansBipolar disorderOxcarbazepineAdverse effectbusiness.industryLithium carbonateCarbamazepineMiddle Agedmedicine.diseaseDermatologySurgeryOtorhinolaryngologychemistryLichenoid eruptionPeriodonticsOral Surgerymedicine.symptomMouth DiseasesbusinessManiamedicine.drugJournal of Oral Pathology and Medicine
researchProduct

Inhibition by Anandamide and Synthetic Cannabimimetics of the Release of [3H]d-Aspartate and [3H]GABA from Synaptosomes Isolated from the Rat Hippoca…

2004

Cannabinoids (CB) can act as retrograde synaptic mediators of depolarization-induced suppression of inhibition or excitation in hippocampus. This mechanism may underlie the impairment of some cognitive processes produced by these compounds, including short-term memory formation in the hippocampus. In this study, we investigated several compounds known to interact with CB receptors, evaluating their effects on K +-evoked release of [ 3H]d-aspartate ([ 3H]d-ASP) and [ 3H]GABA from superfused synaptosomes isolated from the rat hippocampus. [ 3H]d-ASP and [ 3H]GABA release were inhibited to different degrees by the synthetic cannabinoids WIN 55,212-2; CP 55,940, and arachidonyl-2′- chloroethyla…

MaleCannabinoid receptorSettore BIO/14 - FARMACOLOGIAPolyunsaturated Alkamidesmedicine.medical_treatmentHippocampusArachidonic AcidsPharmacologyHippocampal formationDepolarization-induced suppression of inhibitionHippocampusBiochemistryCellular and Molecular Neurosciencechemistry.chemical_compoundglutamate releasemedicineAnimalsRats WistarCannabinoidgamma-Aminobutyric AcidCannabinoid Receptor AgonistsAspartic AcidCannabinoidsChemistryGeneral MedicineAnandamideCyclohexanolsgaba releaseEndocannabinoid systemRatsKineticsnervous systemBiochemistryAnimals Arachidonic Acids Aspartic Acid Calcium Cannabinoids Capsaicin Cyclohexanols gamma-Aminobutyric Acid Hippocampus Kinetics Polyunsaturated Alkamides Potassium Rats Receptors Cannabinoid SynaptosomesPotassiumCalciumlipids (amino acids peptides and proteins)CannabinoidCapsaicinCapsazepineEndocannabinoidsSynaptosomesNeurochemical Research
researchProduct

Effects of Fenoldopam on Intracranial Pressure and Hemodynamic Variables at Normal and Elevated Intracranial Pressure in Anesthetized Pigs

1994

Fenoldopam (FE), a dopamine DA1-receptor agonist, has been introduced for treatment of arterial hypertension and heart failure and for preservation of renal function. Vasodilators are generally assumed to affect all vascular beds including the cerebral circulation. We have evaluated effects of FE-induced (4 micrograms.kg-1.min-1) arterial hypotension on intracranial pressure (ICP) and intraocular pressure (IOP) under conditions of normal and increased intracranial elastance. ICP and IOP responses to hypertension were tested by infusion of angiotensin II (15 micrograms.kg-1.min-1), and the response to hypercapnia was tested by elimination and reintegration of soda lime canisters in the breat…

MaleCentral Venous PressureIntracranial PressureFenoldopamSwineDopamine AgentsHemodynamicsBlood PressureAnesthesia GeneralFenoldopamCerebral autoregulationHypercapniaCerebral circulationCerebrospinal fluidHeart RateAnimalsMedicinePulmonary Wedge PressureAntihypertensive AgentsIntraocular PressureIntracranial pressurePseudotumor CerebriDose-Response Relationship Drugbusiness.industryAngiotensin IIHemodynamicsAngiotensin IIAnesthesiology and Pain MedicineCerebrovascular CirculationAnesthesiaHypertensionFemaleOcular HypertensionVascular ResistanceSurgery2345-Tetrahydro-78-dihydroxy-1-phenyl-1H-3-benzazepineNeurology (clinical)medicine.symptombusinessHypercapniamedicine.drugJournal of Neurosurgical Anesthesiology
researchProduct

Beta‐blockers withdrawal in patients with heart failure with preserved ejection fraction and chronotropic incompetence: Effect on functional capacity…

2020

Abstract Background The pathophysiology of heart failure with preserved ejection fraction (HFpEF) is complex and multifactorial. Chronotropic incompetence (ChI) has emerged as a crucial pathophysiological mechanism. Beta‐blockers, drugs with negative chronotropic effects, are commonly used in HFpEF, although current evidence does not support its routine use in these patients. Hypothesis We postulate beta‐blockers may have deleterious effects in HFpEF and ChI. This work aims to evaluate the short‐term effect of beta‐blockers withdrawal on functional capacity assessed by the maximal oxygen uptake (peakVO2) in patients with HFpEF and ChI. Methods This is a prospective, crossover, randomized (1…

MaleChronotropicheart failure with preserved ejection fractionmedicine.medical_specialtyRandomizationchronotropic incompetenceAdrenergic beta-AntagonistsTrial Designs030204 cardiovascular system & hematologyVentricular Function Leftlaw.inventionBenzodiazepines03 medical and health sciences0302 clinical medicineQuality of lifeRandomized controlled triallawInternal medicinemedicineHumansMulticenter Studies as TopicProspective Studies030212 general & internal medicineRandomized Controlled Trials as TopicHeart FailureDose-Response Relationship Drugbusiness.industryVO2 maxStroke VolumeGeneral Medicineexercise capacityquality of lifeResearch DesignSample size determinationCardiologyFemaleDeprescribingCardiology and Cardiovascular MedicineHeart failure with preserved ejection fractionbusiness
researchProduct

Incremental value and safety of oral ivabradine for heart rate reduction in computed tomography coronary angiography

2012

Background: Heart rate (HR) reduction is essential to achieve optimal image quality and diagnostic accuracy with computed tomography coronary angiography (CTCA). Administration of ivabradine could be an attractive alternative to beta-blockade to reduce HR. Methods: One-hundred-twenty-three patients referred for CTCA were prospectively enrolled. Patients were divided in two groups depending on the absence or presence of chronic beta-blockade treatment. Within the two groups patients were randomized to either no additional premedication or oral ivabradine for 5 days prior to CTCA. In presence of chronic beta-blockade therapy it was shifted to atenolol 50 mg twice a day for 5 days prior to CTC…

MaleCoronary angiographymedicine.medical_specialtyAdministration OralComputed tomographyCoronary Artery DiseaseCoronary AngiographyComputed tomography coronary angiographyHeart RateInternal medicineHeart rateBradycardiamedicineHumansIvabradineIn patientProspective StudiesHeart rate reductionAgedmedicine.diagnostic_testbusiness.industryBenzazepinesMiddle AgedAtenololCoronary heart diseaseBlood pressureAnesthesiaCardiologyFemalePremedicationTomography X-Ray ComputedCardiology and Cardiovascular MedicinebusinessIvabradinemedicine.drugInternational Journal of Cardiology
researchProduct

Dose-Related Concentrations of Neuroactive/Psychoactive Drugs Expected in Blood of Children and Adolescents

2020

PURPOSE Therapeutic drug monitoring is highly recommended for children and adolescents treated with neurotropic/psychotropic drugs. For interpretation of therapeutic drug monitoring results, drug concentrations (C/D) expected in a "normal" population are helpful to identify pharmacokinetic abnormalities or nonadherence. Using dose-related concentration (DRC) factors obtained from pharmacokinetic data, C/D ranges expected under steady state can be easily calculated by multiplication of DRC by the daily dose. DRC factors, however, are defined only for adults so far. Therefore, it was the aim of this study to estimate DRC factors for children and adolescents and compare them with those of adul…

MaleDrugTopiramatePediatricsmedicine.medical_specialtyAdolescentmedicine.medical_treatmentmedia_common.quotation_subjectPopulation030226 pharmacology & pharmacy03 medical and health sciences0302 clinical medicinePharmacokineticsparasitic diseasesHumansMedicinePharmacology (medical)ChildeducationAntipsychoticOxcarbazepinemedia_commonPharmacologyeducation.field_of_studyDose-Response Relationship Drugmedicine.diagnostic_testbusiness.industryAge FactorsArea under the curveAntidepressive AgentsTherapeutic drug monitoringArea Under CurveAnticonvulsantsCentral Nervous System StimulantsFemaleDrug MonitoringbusinessAntipsychotic AgentsHalf-Lifemedicine.drugTherapeutic Drug Monitoring
researchProduct

Behavioral analysis indicates benzodiazepine-tolerance mediated by the benzodiazepine binding-site at the GABA(A)-receptor.

2001

Abstract 1. GABA A -receptor induced changes in locomotion and anxiety-like behaviors were studied in rats using an open-field and an elevated plus-maze. Acute and chronic doses of the benzodiazepine diazepam without and in combination with the GABA uptake inhibitor SKF-89976A were investigated. 2. Fifty-six male rats of the strain PVG/OlaHsd (PVG; 180–200g body wt) were used to assess the influence of the benzodiazepine binding-site to the development of tolerance. Rats were divided into six groups: The first receiving saline (0.9%), the second and third diazepam (10.0 mg/kg) daily for 23 days with or without an acute challenge of 2.0 mg/kg diazepam. The fourth group received diazepam (10.…

MaleElevated plus mazemedicine.medical_specialtymedicine.drug_classGABA AgentsNipecotic AcidsOpen fieldchemistry.chemical_compoundOral administrationInternal medicineMedicineAnimalsheterocyclic compoundsMaze LearningBiological PsychiatryPharmacologyBenzodiazepineDiazepamGABAA receptorbusiness.industryReceptors GABA-ARatsEndocrinologychemistryAnti-Anxiety AgentsExploratory BehaviorSKF-89976AbusinessReuptake inhibitorDiazepammedicine.drugProgress in neuro-psychopharmacologybiological psychiatry
researchProduct

In vivo molecular imaging of the GABA/benzodiazepine receptor complex in the aged rat brain

2012

The GABA-ergic system, known to regulate neural tissue genesis during cortical development, has been postulated to play a role in cerebral aging processes. Using in vivo molecular imaging and voxel-wise quantification, we aimed to assess the effects of aging on the benzodiazepine (BDZ) recognition site of the GABA A receptor. To visualize BDZ site availability, [C-11]-flumazenil microPET acquisitions were conducted in young and old rats. The data were analyzed and region of interest analyses were applied to validate the voxel-wise approach. We observed decreased [C-11]-flumazenil binding in the aged rat brains in comparison with the young control group. More specifically, clusters of reduce…

MaleFlumazenilReceptor complexCerebellumAgingHippocampusMolecular imagingMidbrainGABAmedicineRadioligandAnimalsReceptorBenzodiazepineChemistryGeneral NeuroscienceBrainReceptors GABA-ACortex (botany)Molecular ImagingRatsmedicine.anatomical_structurenervous systemFlumazenilPositron emission tomography (PET)Neurology (clinical)Geriatrics and GerontologyNeuroscienceDevelopmental Biologymedicine.drugProtein Binding
researchProduct